ACOR - Acorda's INBRIJA Receives Thumbs Up From FDA And Thumbs Down From Analysts
It has been a tough year for Acorda Therapeutics (ACOR) with their ongoing litigation over 4 patents for the company's moneymaker AMPYRA drug for multiple sclerosis "MS". AMPYRA generated ~$153M in sales during Q3, but with generics grabbing the lion's share of the market, we can expect dismal AMPYRA sales in the upcoming quarters.
However, the company just had a last minute victory with an FDA approval for their Parkinson's disease "PD" product INBRIJA. The company believes INBRIJA could eventually generate up to $800 million in peak sales. Unfortunately, many analysts are